<DOC>
	<DOCNO>NCT01059136</DOCNO>
	<brief_summary>Study hypothesis : An early blockade aldosterone receptor initiate first medical contact acute myocardial infarction may reduce major cardiovascular event within 6 month occurrence myocardial infarction . Primary efficacy criterion : The 6 month rate composite death , resuscitate cardiac arrest , potentially lethal ventricular arrhythmia , indication implantation implantable cardioversion device , occurrence aggravation heart failure . Primary objective : To demonstrate superiority aldosterone blockade initiate soon possible within 72 hour onset acute myocardial infarction top standard therapy , compare standard therapy alone , without reperfusion therapy . Study design : Prospective , multi-centre randomise , open label 2 parallel study arm .</brief_summary>
	<brief_title>Aldosterone Blockade Early After Acute Myocardial Infarction</brief_title>
	<detailed_description>Rational : The blockade renin-angiotensin-aldosterone ( RAA ) pathway angiotensin conversion enzyme inhibitor ( ACEI ) one corner stone management heart failure well management ischemic heart disease , especially acute myocardial infarctionHigh plasma aldosterone level associate direct indirect toxic effect myocardium . ACEIs associate partial temporary reduction plasma aldosterone levels.The RALES randomize control trial show reduction mortality associate use selective aldosterone receptor blocker spironolactone , top standard therapy include ACEIs set NYHA 3-4 chronic heart failure . The EPHESUS randomize control trial show reduction mortality associate use another selective aldosterone receptor blocker Eplerenone , initiate 3 14 day acute myocardial infarction complicate clinical heart failure leave ventricular ejection fraction &lt; 40 % .Both previous study also report rapid reduction global arrhythmia-related mortality , within 30 day initiation medication.Such benefit report delayed initiation aldosterone block , aldosterone high level presentation acute myocardial infarction , rapid decrease within day admission . Furthermore high aldosterone level admission associate adverse outcome independent heart failure . The ALBATROSS trial : Hypothesis : An early blockade aldosterone receptor initiate first medical contact acute myocardial infarction may reduce major cardiovascular event within 6 month occurrence myocardial infarction . Primary objective : To demonstrate superiority aldosterone blockade initiate soon possible within 72 hour onset acute myocardial infarction top standard therapy , compare standard therapy alone , without reperfusion therapy .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>1 . Age ≥ 18 an 2 . Ischemic symptom ≥ 20 minute 3 . Randomization within 72 hour symptom onset 4 . Electrocardiogram biological evidence myocardial infarction : ST segment elevation ≥ 2 mm ≥ 2 adjacent precordial derivation ST segment elevation ≥ 1 mm ≥ 2 adjacent peripheral derivation New leave bundle branch block New significant Q wave ≥ 2 adjacent peripheral derivation Troponin level ≥3 time upper local limit normal value Thrombolysis In Myocardial Infarction ( TIMI ) nonST elevation myocardial infarction risk score ≥ 3 . 5 . Patients health insurance 6 . Written inform consent obtain : 1. patient 2 . A member family person confidence patient unable provide inform consent 1 . Contraindication know intolerance study drug 2 . Patients already treat aldosterone blocker diseases systemic hypertension ( e.g . primary hyperaldosteronism ) 3 . Hyperkaliemia &gt; 5.5 mmol/l time randomization 4 . Renal function impairment : Plasma creatinin level &gt; 220 µmol/l and/or Creatinin clearance 30 ml/min 5 . Severe liver deficiency ( ChildPugh Class 3 ) 6 . Pregnant breast feed woman , woman desire pregnancy within 6 month randomization 7 . Patients already include another biomedical intervention trial 8 . Life expectancy &lt; 1 year 9 . Cardiac arrest lasting ( ECM ) &gt; 10 minute prior randomization 10 . Patient unable unwilling comply treatment followup visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Myocardial infarction</keyword>
	<keyword>Outcome</keyword>
	<keyword>Aldosterone</keyword>
	<keyword>Spironolactone</keyword>
</DOC>